



VIDAS[®] 3

Immunoassay Reference Guide



With more than 24 years of proven immunochemistry, bioMérieux has the largest installed base of immunoassay systems worldwide, with more than 30,000 VIDAS instruments. The addition of the VIDAS 3 to the family of analyzers expands on the exceptional accuracy and flexibility, with more automated and specialty assays for a variety of applications.



For more information, contact your local bioMérieux, Inc. representative.
Customer Service: (800) 682-2666 • www.biomerieux-usa.com/vidas

PIONEERING DIAGNOSTICS



VIDAS® 3 Assay Reference Sheet

ASSAY NAME	PRODUCT NUMBER	REPORTABLE RANGE	COMPATIBILITY*	CPT CODE (MODIFIER)
CRITICAL AND EMERGENCY CARE				
VIDAS B-R-A-H-M-S PCT™ (Procalcitonin)	30450-01	0.05-200 ng/ml	1	84145
VIDAS D-DIMER EXCLUSION™ II	30455-01	45-10,000 ng/ml	N/A	85379
INFECTIOUS DISEASES				
VIDAS SARS-COV-2 IgM	423833-01	Qualitative	8	86769
VIDAS SARS-COV-2 IgG	423834-01	Qualitative	8	86769
VIDAS MEASLES IgG	30219	Qualitative	2	86765
VIDAS MUMPS IgG	30218	Qualitative	2	86735
VIDAS RUBELLA IgG	30226	0-250 IU/ml	3	86762
VIDAS VARICELLA IgG	30217	Qualitative	2	86787
VIDAS LYME IgG II	417401	Qualitative	8	86618 (QW)
VIDAS LYME IgM II	416436	Qualitative	8	86618 (QW)
VIDAS <i>C. difficile</i> TOXIN A&B (CDAB)	30118-01	Qualitative	N/A	87324
VIDAS <i>C. difficile</i> GDH	30125-01	Qualitative	N/A	87449 (QW)
VIDAS <i>H. pylori</i>	30192-01	Qualitative	3	86677
VIDAS TOXO IgG II	30210-01	0-300 IU/ml	3	86777
VIDAS TOXO IgM	30202-01	Qualitative	3	86778
VIDAS CMV IgG	30204-01	0-400 AU/ml	3	86644
VIDAS CMV IgM	30205-01	Qualitative	N/A	86645
REPRODUCTIVE HORMONES				
VIDAS HCG	30405-01	2-1500 mIU/ml	5	84702

*Matching numbers indicate VIDAS assays that can be run using the same protocol on the VIDAS instruments.

To place an order, visit

www.biomerieuxDIRECT.com

VIDAS SARS-COV-2: These tests have not been FDA cleared or approved but have been authorized for emergency use by FDA under an EUA for use by authorized laboratories. These tests have been authorized only for detecting IgG and IgM antibodies against SARS-CoV-2, not for any other viruses or pathogens. The emergency use of these tests is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.